華蟾素注射液是我國(guó)自行研制開發(fā)的二類新藥，是由中華大蟾蜍Bufo bufo gargarizans皮提取的主要成分經(jīng)加工制成的水溶性制劑，具有良好的抗腫瘤作用，是我國(guó)臨床中應(yīng)用較廣的抗腫瘤藥物，尤其對(duì)肝癌的效果較好。其不僅對(duì)多種肝癌細(xì)胞有殺傷和抑制作用，而且許多臨床醫(yī)生發(fā)現(xiàn)華蟾素單用及聯(lián)合介入治療等手段治療肝癌均收到良好的效果。對(duì)華蟾素抗肝癌的基礎(chǔ)和臨床最新研究進(jìn)行綜述，為進(jìn)一步開發(fā)和應(yīng)用提供參考。

Cinobufacini Injection is the second class new drug independently developed by China, which is water-soluble preparations processed by the main component of Bufo bufo gargarizans skin. As a kind of Chinese materia medica with antitumor effect, Cinobufagin Injection is widely used in clinical practice, especially in anti-liver cancer. It could not only inhibit and kill various kinds of hepatoma carcinoma cells, but also be satisfactory effective in treating patients with liver cancer either when applied lonely or together with interventional therapy. This paper will rewiew the latest progress on the basic and clinical application in treating liver cancer of Cinobufagin Injection..